admin

KQED and the John S. and James L. Knight Foundation each invested $1.25 million in Matter Ventures, a media startup accelerator they’ve created with help from Public Radio Exchange.

Corey Ford, who ran the accelerator Runway, is CEO of Matter Ventures.

The accelerator — publicized last year as Public Media Accelerator — will pick startups for its four month program and pay them a $50,000 investment as they work in shared space in the South Park area of San Francisco.

A new $50 million investment fund will provide seed capital to launch new businesses that use technologies from government and university research labs in the Maryland, Virginia, Delaware and the District of Columbia.

The Chesapeake Regional Innovation Fund will provide seed capital for startups and emerging technology companies focused on innovations in energy, life sciences and security. The first investments are anticipated for later in 2013.

Early stage startups already see New York as a hub for media, advertising and fashion. But the city is starting to build up its name in health tech as well.

At the start of this year, both Startup Health and Blueprint Health – two incubator-type programs that provide funding, mentorship and connections – announced their first classes of startups.  Then, in October, the New York Digital Health Accelerator, backed by the New York eHealth Collaborative nonprofit and the private New York City Fund, introduced its own batch of health tech startups.

As of Friday, the Division of Economic and Community Outreach changed its name to the Division of Innovation and Applied Research.

The department “serves as a point of entry for businesses, non-profit organizations, government agencies, and community members interested in collaborating with the University,” according to Towson’s website.

The name change is a small part of the work that Dyan Brasington, the vice president for Division of Innovation and Applied Research, is doing under President Maravene Loeschke.

The Johns Hopkins University performed $2.1 billion in medical, science, and engineering research in fiscal 2011, making it the leading U.S. academic institution in total research and development spending for the 33rd year in a row, according to a new National Science Foundation ranking.

The university also once again ranked first on the NSF’s separate list for federally funded research and development, spending $1.88 billion in FY2011 on research supported by NSF, NASA, the National Institutes of Health, and the Department of Defense. In FY2002, Johns Hopkins became the first university to reach the $1 billion mark on either list, recording $1.14 billion in total research and $1.023 billion in federally sponsored research that year.

QIAGEN N.V. has announced the first product launches in its initiative to advance routine workflows in next-generation sequencing (NGS) applications. At the annual meeting of the American Society of Human Genetics (ASHG) in San Francisco, QIAGEN will present four new products that improve critical sample preparation processes in the pre-analytical phase of next-generation sequencing. At ASHG, QIAGEN also will provide an outlook on additional pre-analytical products under development for advanced NGS workflow solutions, which are planned for launch in early 2013.

The QIAGEN pre-analytical products are “universal,” compatible with any NGS platform in the market and functional in a wide range of NGS applications. They represent the first launches in the QIAGEN initiative unveiled earlier this year, which aims to integrate sample preparation products and novel assay technologies into complete workflows for next-generation sequencing.

After more than two weeks crisscrossing the state with stops in Ocean City, La Plata, Hagerstown and pretty much everywhere in between, the bright yellow Pitch Across Maryland bus rolled into Merriweather Post Pavilion in Columbia on Friday.

There was music, booze, advice for entrepreneurs and, of course, more business pitches in the make-shift studio in the back of the bus.

Organizers expected to collect 40 or so pitches total at the 25 stops across the state when the bus pulled out of Columbia on Sept. 11 to start the tour.

Fyodor Biotechnologies, a Baltimore-based diagnostic and biopharmaceutical company, announced today that the National Science Foundation has awarded the company a Small Business Innovation Research (SBIR) Phase I grant. With the $150,000 funding, Fyodor plans to develop a novel recombinant antibody to be used in a urine-based test for the point-of-need detection of Leptospirosis.

Leptospirosis is a worldwide, potentially serious but treatable bacterial disease that occurs in humans and domestic animals, including pets. The causative bacteria are spread through the urine of infected animals, which can get into water (including swimming pools) or soil, and can survive there for weeks to months. Clinical signs of leptospirosis are nonspecific, and current diagnostic tools rely on complicated testing methods that are unsuitable for use in many point- of-need settings. Therefore, a simple one-step test is urgently needed for rapid diagnosis.

The deadline for contract proposal submissions is Tuesday, November 13th, 2012

Details and solicitation materials are available at the NIH SBIR Website in the Funding Opportunity Table: http://sbir.nih.gov/.

Applications must respond to a topic in the solicitation. All submissions must be on paper. Contract proposal forms are available electronically at PHS 2013-1 PDF [http://grants.nih.gov/grants/funding/SBIRContract/PHS2013-1.pdf] or MS Word [http://grants.nih.gov/grants/funding/SBIRContract/PHS2013-1.doc]. Please follow the direc­tions in the solicitation very carefully.